US2017246357A1PendingUtilityA1

Hydrogel compositions for use in cell expansion and differentiation

58
Assignee: WISCONSIN ALUMNI RES FOUNDPriority: Apr 10, 2014Filed: May 16, 2017Published: Aug 31, 2017
Est. expiryApr 10, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:William L. MurphyMatthew Brian ParlatoJames A MolendaNgoc Nhi Le
B01J 19/0046A61L 31/145G01N 33/4833G01N 21/6452A61L 29/16A61L 2300/80B01J 2219/00596C12N 2533/20C12N 2533/30C12N 2537/10C12N 5/0606G01N 2610/00G01N 33/5005A61K 47/42
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Hydrogel compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to promote cellular expansion and/or cellular differentiation of various cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A hydrogel composition comprising an 8-arm, 20 kDa polyethylene glycol functionalized with norbornene, a crosslinking peptide, and a cell adhesion peptide. 
     
     
         2 . The hydrogel composition of  claim 1  comprising at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38). 
     
     
         3 . The hydrogel composition of  claim 2  comprising a shear modulus range of from about 2 kPa to about 12 kPa. 
     
     
         4 . The hydrogel composition of  claim 2  comprising a shear modulus of from about 1.8 kPa to about 33 kPa. 
     
     
         5 . The hydrogel composition of  claim 1  comprising a concentration of polyethylene glycol of from about 36 mg/mL to about 160 mg/mL. 
     
     
         6 . The hydrogel composition of  claim 1  comprising a concentration of polyethylene glycol of from about 36 mg/mL to about 70 mg/mL. 
     
     
         7 . The hydrogel composition of  claim 1  comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38). 
     
     
         8 . The hydrogel composition of  claim 7  comprising a shear modulus of from about 3 kPa to about 16 kPa. 
     
     
         9 . The hydrogel composition of  claim 1  further comprising an immobilized low molecular weight heparin. 
     
     
         10 . The hydrogel composition of  claim 1 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof. 
     
     
         11 . The hydrogel composition of  claim 1  comprising an extent of crosslinking, wherein the extent of crosslinking is from about 35% to about 75%. 
     
     
         12 . A hydrogel composition comprising a polyethylene glycol functionalized with norbornene, a crosslinking peptide, and at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38), wherein the hydrogel composition comprises a shear modulus in the range of about 1.8 kPa to about 33 kPa. 
     
     
         13 . The hydrogel composition of  claim 12 , wherein the shear modulus is in the range of about 2 kPa to about 12 kPa. 
     
     
         14 . The hydrogel composition of  claim 12  comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38). 
     
     
         15 . The hydrogel composition of  claim 14 , wherein the shear modulus is in the range of from about 3 kPa to about 16 kPa. 
     
     
         16 . The hydrogel composition of  claim 12 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof. 
     
     
         17 . A hydrogel composition comprising a polyethylene glycol functionalized with norbornene, a crosslinking peptide, and at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38), wherein the hydrogel composition comprises a concentration of polyethylene glycol of from about 36 mg/mL to about 160 mg/mL. 
     
     
         18 . The hydrogel composition of  claim 17 , wherein the concentration of polyethylene glycol is in the range of from about 36 mg/mL to about 70 mg/mL. 
     
     
         19 . The hydrogel composition of  claim 17  comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38). 
     
     
         20 . The hydrogel composition of  claim 17 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof.

Join the waitlist — get patent alerts

Track US2017246357A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.